AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05183477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fast track
Description: short cut for the request of xrays directly at triage
Study NCT05183477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal pathway
Description: x-ray would be required according to doctor's clinical evaluation.
Study NCT06507371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard short-course radiotherapy
Description: radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous (IV) infusion or SC injection.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous (IV) infusion or SC injection.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline tablet will be administered orally.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline capsule will be administered orally.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin lotion will be used as topical application on the scalp.
Study NCT06120140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine solution will be used as topical application on hands and feet.
Study NCT06120140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noncomedogenic skin moisturizer
Description: Noncomedogenic skin moisturizer will be used as topical application.
Study NCT04208217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modeling to Learn (MTL)
Description: Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
Study NCT04208217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual quality improvement (QI)
Description: Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
Study NCT06150157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-88549968
Description: JNJ-88549968 will be administered.
Study NCT04879199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static stability measurement
Description: The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s.
Study NCT04879199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic stability measurement
Description: The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized.
Study NCT04732208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colour fundus photography
Description: Fundus images will be captured before and after administration of mydriatic agent
Study NCT04859660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
Study NCT04859660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
Study NCT05076149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study NCT05076149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablets for oral administration.
Study NCT05076149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.
Study NCT05076149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-121/TEZ/D-IVA)
Description: Placebo matched to VX-121/TEZ/D-IVA for oral administration.
Study NCT05076149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Study NCT05076149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration.
Study NCT04611191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The intervention involves a control condition with participants continuing their normal way of living
Study NCT06429345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 Milligrams Oral Capsule
Description: Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
Study NCT06429345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 1: How We Evolved - Threat, Impulse, and Soothing Systems
Description: The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 2: Threat and Self-Compassion
Description: The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 3: Unraveling the Knots of Desire and Patterns
Description: The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 4: Internalizing compassion
Description: The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 5: Me and others - Expanding the circle
Description: The a compassionate letter practice with the participants will continue for 15 minutes. Courtesy meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 6: Growing happiness
Description: The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 7: Weaving Wisdom and Compassion into Daily Life
Description: Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants.
Study NCT05891223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 8: Living with the Heart
Description: The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application.
Study NCT06277882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAVRIX
Description: intramuscular injections
Study NCT06277882 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX
Description: intramuscular injections
Study NCT06269380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.
Study NCT06269380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy sampling
Description: The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.
Study NCT04982354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
Study NCT06181032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;
Study NCT06181032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250 mg, po, QD, Q3W;
Study NCT04982354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
Study NCT06181032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;
Study NCT06181032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.
Study NCT01273428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP011-101
Study NCT01273428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HP-828-101
Study NCT01273428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study NCT06419244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myosteatosis
Description: Determination of myosteatosis by imaging
Study NCT04919512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered.
Study NCT04919512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study NCT05063461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation
Description: For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
Study NCT05063461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin incision
Description: Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
Study NCT06272409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEP114
Description: DEP114 oral solution
Study NCT06272409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine 0.5 MG/ML
Description: Desloratadine oral solution
Study NCT05092347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5459
Description: Administered by intravenous (IV) infusion
Study NCT05092347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5458
Description: Administered by intravenous (IV) infusion
Study NCT05158777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.
Description: live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
Study NCT05158777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
Description: live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
Study NCT04982354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg/dose every six hours x 12 doses administered intravenously
Study NCT04982354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m2/day x 2 doses administered intravenously
Study NCT04982354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/day x 5 doses administered intravenously
Study NCT04982354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
Description: Allogeneic stem cell transplant infused intravenously
Study NCT05204173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab, paclitaxel and S-1
Description: Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
Study NCT06112639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANCEREX-DTx
Description: DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context.
Study NCT06112639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional dance-based program
Description: Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
Study NCT06112639 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Educational Program
Description: Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
Study NCT04722172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
Study NCT04722172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered during Cycles 2-7.
Study NCT04891770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Administered as film-coated oral tablets
Study NCT05904886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study NCT05904886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study NCT05904886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT05904886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT05904886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
Study NCT05904886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
Study NCT05636176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
Study NCT05636176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
Study NCT06333860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Solution for Subcutaneous (SC) injection
Study NCT06333860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Oral tablet
Study NCT06450353 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Ancestry Questionnaires
Description: Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
Study NCT04891770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: Administered as a sub-cutaneous (SC) injection